Devices that help educate young doctors and enable safe, minimally invasive surgery are needed. Eureka is a surgical artificial intelligence (AI) system that can intraoperatively highlight loose connective tissues (LCTs) in the dissected layers and nerves in the surgical field displayed on a monitor. In this study, we examined whether AI navigation (AIN) with Eureka can assist trainees in recognizing nerves during colorectal surgery. In left-sided colorectal surgery (n = 51, between July 2023 and February 2024), Eureka was connected to the laparoscopic system side by side, and the nerve was highlighted on the monitor during the surgery. We examined the rate of failure to recognize nerves by trainee surgeons over a total of 101 scenarios after it was recognized intraoperatively by the supervising surgeon (certified by the Japanese Society of Endoscopic Surgery). We also examined the frequency of nerve recognition by the trainee physicians viewing the Eureka monitor when recognition was not possible (recognition assistance rate). The nerve recognition failure rate and recognition assistance rate with AIN were as follows: right hypogastric nerve during sigmoid colon mobilization, 44/101 (43.6%) and 19/44 (43.2%); left hypogastric nerves during dissection of the dorsal rectum, 27/101 (26.7%) and 13/27 (48.1%); right lumbar splanchnic nerves, 32/101 (31.7%) and 29/32 (90.6%); left lumbar splanchnic nerves, 44/101 (43.6%) and 39/44 (88.6%); and pelvic visceral nerves during dissection of the dorsal rectum, 29/45 (64.4%) and 6/29 (20.7%), respectively. Although the rate of recognition with assistance from AIN differed for the different nerves, this system can potentially assist in anatomic recognition, enhance surgical education, and contribute to nerve preservation. Improvement of AI navigation in minimally invasive surgery and examination of its intraoperative support and educational effectiveness. Research Ethics Committee of the Kawaguchi Municipal Medical Center (Saitama, Japan) approval number: 2022-27.
To clarify the mechanism of progression and acquired drug resistance of leukemia, we searched for an overexpressed gene in drug-resistant leukemia cells and identified an approximately 5-kb transcript by using the subtraction method. The nucleotide sequence of the gene was highly homologous to those of human endogenous retrovirus (HERV) transcripts. Reverse transcriptase-polymerase chain reaction (RT-PCR) revealed that the gene was overexpressed in cells from 6 childhood acute lymphoblastic leukemia patients (60%) but not in bone marrow cells at remission. Peripheral blood mononuclear cells from normal controls (n=11) and bone marrow cells from non-leukemia patients (n=13) did not express the gene. These findings indicate that the gene may play a role in leukemogenesis and may be a novel leukemia marker. Further studies on the functional role of the gene are needed.
Modification of drug forms on and cancer agents followed the concept of drug delivery system is one of many attempts to obtain full efficacy of chemotherapy against cancer, and reduce its side-effects. In this paper, we made a basic research to give chemotherapy with cisplatin in liposome microcapsules an assured status in expecting the efficacy of blood vessel-embolism produced by the capsule itself, and gradual discharge of the agent from those capsules.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is rising globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome aggravation. We describe SARS-CoV-2-positive patients, two of whom were in a critical condition and one of whom was in a severe condition, who were administered favipiravir for their deteriorating conditions and cured.
The aim of the present study was to evaluate the role of interleukin (IL)-6-634 polymorphism in neonatal disorders such as bronchopulmonary dysplasia (BPD) and periventricular leukomalacia (PVL) in very low-birthweight (VLBW) infants.This prospective cohort study included 202 infants (gestational age at birth, 23-34 weeks; birthweight, 500-1499 g). Genotypic analysis (polymerase chain reaction-restriction fragment length polymorphism) was performed with DNA extracted from whole-blood samples.Genotype distribution (66.8% CC, 28.2% CG, 5.0% GG) was similar to that in the adult Japanese population. BPD occurred in 85 infants (42.1%) among 202 VLBW infants. The duration of O(2) therapy in infants with CG/GG genotypes was significantly longer than that in infants with the CC genotype (CG/GG vs CC: 40.3 ± 52.2 days vs 28.4 ± 32.6 days, P < 0.05), but the prevalence of BPD was not associated with the CG/GG genotype (CG/GG, 40.0%; CC, 46.3%, P= 0.24). Infants with CG/GG genotypes were more likely to have received postnatal corticosteroid therapy for BPD than those with the CC genotype (CG/GG vs CC: 20.9% vs 11.1%, P = 0.05). PVL occurred in six infants (3.0%). There was no significant difference in the prevalence of PVL among IL-6-634 polymorphisms (CG/GG, 3.0%; CC, 3.0%, P = 0.65).IL-6-634 polymorphism is associated with duration of oxygen therapy in VLBW infants. This suggests that the IL-6-634 polymorphism G allele is an aggravating factor of BPD. IL-6-634 polymorphism is not associated with PVL.
